INVENTIVA (EPA:IVA) | Finanzwire

Basculer en Français

8597	Companies
140147	Keywords
76070	Articles
74833	Press releases

Home
Companies
INVENTIVA

BRIEF

published on 03/26/2025 at 21:05, 7 days 16 hours ago

Inventiva unveils its 2024 financial results and strategic projects

Strategic Reorganization 2024 Financial Results Research & Development Lanifibranor Structured Financing
PRESS RELEASE

published on 03/26/2025 at 21:00, 7 days 16 hours ago

Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented

Revenues Financial Results Inventiva Cash Equivalents NATiV3 Phase 3 Trial
BRIEF

published on 03/19/2025 at 21:05, 14 days 16 hours ago

Inventiva Announces 2024 Full-Year Financial Results Schedule

Financial Results Webcast Inventiva Lanifibranor MASH Treatment
PRESS RELEASE

published on 03/19/2025 at 21:00, 14 days 16 hours ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva schedules 2024 Full-Year Financial Results presentation on March 27, 2025. Webcast available. Company focused on small molecule therapies for MASH

Presentation 2024 Financial Results Inventiva MASH Small Molecule Therapies
BRIEF

published on 02/26/2025 at 22:05, 1 month 4 days ago

Inventiva's Lanifibranor Shows Promise in Portal Hypertension Study

Preclinical Study Inventiva Liver Disease Lanifibranor Portal Hypertension
PRESS RELEASE

published on 02/26/2025 at 22:00, 1 month 4 days ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Inventiva announces publication in Biomedicine & Pharmacotherapy of preclinical study results indicating lanifibranor's effectiveness in improving portal hypertension, potentially addressing complications of chronic liver diseases

Preclinical Study Inventiva Lanifibranor Portal Hypertension Biomedicine & Pharmacotherapy
BRIEF

published on 02/20/2025 at 22:05, 1 month 10 days ago

Inventiva launches clinical development of lanifibranor in Japan

Inventiva Phase 1 MASH Lanifibranor Hepalys Pharma
PRESS RELEASE

published on 02/20/2025 at 22:00, 1 month 10 days ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva and Hepalys Pharma, Inc. initiate clinical development program of lanifibranor in Japan with dosing of first participant in Phase 1 trial, marking significant progress in partnership

Clinical Trial Japan Inventiva Lanifibranor Hepalys Pharma
BRIEF

published on 02/10/2025 at 22:05, 1 month 20 days ago

Inventiva Announces Preliminary Financial Results for 2024

Financial Results Funding Strategy Inventiva Lanifibranor
PRESS RELEASE

published on 02/10/2025 at 22:00, 1 month 20 days ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development

Revenues Financial Results 2024 Fiscal Year Inventiva Lanifibranor

1 2 ... 6

Accesswire

Published on 04/03/2025 at 13:00, 15 minutes ago

30,000m Drilling Program Announced for AurMac Gold Project, Yukon
Published on 04/03/2025 at 13:00, 15 minutes ago

Grid Metals Corp. Reports Makwa Project Advancing to Drill Stage
Published on 04/03/2025 at 11:00, 2 hours 15 minutes ago

Focus Graphite Advanced Materials Initiates Validation Testing of Lac Knife Anode Materials with Leading Battery Innovator C4V
Published on 04/03/2025 at 05:10, 8 hours 5 minutes ago

Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 11 hours 40 minutes ago

GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm

View all ACCESSWIRE

EQS Group

Published on 04/03/2025 at 12:15, 1 hour ago

Baisha’s San Yue San Festival: International Students Immersed in Vibrant Ethnic Culture
Published on 04/03/2025 at 12:00, 1 hour 15 minutes ago

Linde Announces First Quarter 2025 Earnings and Conference Call Schedule
Published on 04/03/2025 at 11:42, 1 hour 33 minutes ago

Resolutions of the 2025 annual general meeting of Ørsted A/S
Published on 04/03/2025 at 11:15, 2 hours ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/03/2025 at 09:00, 4 hours 15 minutes ago

Partners Group to invest in Gestcompost, the largest organic waste manager in Spain, through a continuation fund

Les Echos

Published on 04/03/2025 at 09:45, 3 hours 29 minutes ago

GUILLEMOT CORPORATION: Information regarding the total number of voting rights and shares 31/03/2025
Published on 04/03/2025 at 09:35, 3 hours 40 minutes ago

Disclosure of Share Capital and Voting Rights as of March 31, 2025
Published on 04/03/2025 at 08:45, 4 hours 30 minutes ago

Baikowski: Strong growth in 2024 full-year results
Published on 04/03/2025 at 08:00, 5 hours 15 minutes ago

Availability of preparatory documents for the Annual Shareholders’ Meeting of OPmobility SE
Published on 04/03/2025 at 00:37, 12 hours 38 minutes ago

Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code

View all LES ECHOS COMFI WIRE